IKCS North America 2022

Conference Coverage

Researchers Characterize Gut Microbiome of Patients With mRCC and Sarcopenia

Sarcopenic patients with metastatic renal cell carcinoma have distinct bacterial populations that express metabolic pathways associated with a catabolic state.

Live Bacterial Product Improves Outcomes in Metastatic Renal Cell Carcinoma

CBM588, a live bacterial product, improves the efficacy of first-line treatment with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma, a study suggests.

RCC Trials Use “Potentially Excessive” Exclusion Criteria

Renal cell carcinoma trials conducted in the past 10 years used exclusion criteria deemed potentially excessive by ASCO and FCR.

Characteristics of Renal Cell Carcinoma Differ According to Genetic Ancestry

Among patients with renal cell carcinoma, clinical presentation, extent of disease, and germline and somatic alterations differ according to genetic ancestry.

Lenvatinib Plus Pembrolizumab Improves PFS2, OS in Advanced Renal Cell Carcinoma

Second progression-free survival is significantly longer with lenvatinib-pembrolizumab than with sunitinib in patients with advanced renal cell carcinoma.

Intratumoral Vaccination Does Not Appear to Benefit Patients With mRCC

Adding ilixadencel to treatment with sunitinib does not appear to improve outcomes in patients with metastatic renal cell carcinoma undergoing nephrectomy.

RCC With NF2 Mutations Associated With Metastatic Disease, Poor Survival

Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.

Tivozanib Improves Long-Term PFS in Rel/Ref Metastatic Renal Cell Carcinoma

Tivozanib improves long-term progression-free survival, when compared with sorafenib, in patients with relapsed or refractory metastatic renal cell carcinoma, an analysis suggests.

Health Care Utilization Lower With Pembrolizumab-Axitinib Than With Ipilimumab-Nivolumab

Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.

Immunotherapy Combos Overtake TKI Monotherapy as First-Line Treatment for mRCC

Immunotherapy-based combinations have overtaken TKI monotherapy as the most-used first-line treatment for mRCC in US oncology clinics, a study suggests.

RCC Patients Have 10-Fold Higher Risk of End-Stage Renal Disease

The risk for end-stage renal disease is 10 times higher in patients with renal cell carcinoma than in the general population, a study suggests.

AUA Surveillance Guidelines May Improve Metastasis-Free Survival

Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.